Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the V1H Gene Family

Mattia Bonsignori, Justin Pollara, M. Anthony Moody, Michael D. Alpert, Xi Chen, Kwan-Ki Hwang, Peter B. Gilbert, Ying Huang, Thaddeus C. Gurlay, Daniel M. Kozink, Dawn J. Marshall, John F. Whitesides, Chun-Yen Tsao, Jaranit Kaewkungwal, Sorachai Nitayaphan, Punnutee Pitsuthitthum, Supachai Rerk-Ngarm, Jerome H. Kim, Nelson L. Michael, Georgia D. Tomas, David C. Montefori, George K. Lewis, Anthony DeVico, David T. Evans, Guido Ferrari, Hua-Xin Liao, and Barton F. Haynes

Duke University Medical Center, Durham, North Carolina, USA; Harvard Medical School, Boston, Massachusetts, USA; Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA; Tropical Hygiene, Mahidol University, Bangkok, Thailand; Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand; Clinical Tropical Medicine, Mahidol University; Bangkok, Thailand; Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand; U.S. Military HIV Research Program, Rockville, Maryland, USA; and Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland

The ALVAC-HIV/AIDSvAX-B/E RV144 vaccine trial showed an estimated efficacy of 31%. RV144 secondary immune correlate analysis demonstrated that the combination of low plasma anti-HIV-1 Env IgA antibodies and high levels of antibody-dependent cellular cytotoxicity (ADCC) inversely correlate with infection risk. One hypothesis is that the observed protection in RV144 is partially due to ADCC-mediating antibodies. We found that the majority (73 to 90%) of a representative group of vaccinees displayed plasma ADCC activity, usually (96.2%) blocked by competition with the C1 region-specific A32 Fab fragment. Using memory B-cell cultures and antigen-specific B-cell sorting, we isolated 23 ADCC-mediating nonclonally related antibodies from 6 vaccine recipients. These antibodies targeted A32-blockable conformational epitopes (n = 19), a non-A32-blockable conformational epitope (n = 1), and the gp120 Env variable loops (n = 3). Fourteen antibodies mediated cross-clade target cell killing. ADCC-mediating antibodies displayed modest levels of V-heavy (VH) chain somatic mutation (0.5 to 1.5%) and also displayed a disproportionate usage of VH1 family genes (74%), a phenomenon recently described for CD4-binding site broadly neutralizing antibodies (bNAbS). Maximal ADCC activity of VH1 antibodies correlated with mutation frequency. The polyclonality and low mutation frequency of these VH1 antibodies reveal fundamental differences in the regulation and maturation of these ADCC-mediating responses compared to VH1 bNAbS.

The RV144 ALVAC-HIV (vCP1521) prime/AIDSvAX B/E boost clinical trial provided the first evidence of vaccine-induced protection from acquisition of human immunodeficiency virus type 1 (HIV-1) infection (39). Analysis of immune correlates of risk of infection demonstrated that antibodies (Ab) targeting the Env gp120 V1/V2 region inversely correlated with infection risk, while IgA Env-binding antibodies to Env directly correlated with infection risk (17). In addition, secondary immune correlate analyses, low plasma IgA Env antibody levels in association with high levels of antibody-dependent cellular cytotoxicity (ADCC) were inversely correlated with infection risk (17). Thus, one hypothesis is that the observed protection in RV144 is due, in a subset of vaccinees, to ADCC-mediating antibodies.

The importance of ADCC responses has been reported in chronically HIV-1-infected individuals (3, 13, 22) and in HIV-1 vaccine studies in nonhuman primates (14, 15, 18, 45). Baum et al. reported an inverse correlation between titers of HIV-1 gp120-specific ADCC antibodies and the rate of disease progression in humans (3). Moreover, HIV-1-infected elite controllers who had undetectable viremia showed higher ADCC antibody titers than infected individuals with viremia (22). In nonhuman primates, administration of vaccine candidates elicited ADCC antibody titers that correlated with control of virus replication after mucosal challenge with a pathogenic simian immunodeficiency virus (SIV) (2, 15). More recently, different groups have reported that titers of nonneutralizing ADCC antibodies are associated with control of viremia against primary SIV infection (14, 18, 45). While antibodies against multiple epitopes can mediate ADCC, it has been recently reported that the A32 monoclonal antibody (Mab), recognizing a conformational epitope in the C1 region of HIV-1 Env gp120 (53), could mediate potent ADCC activity and could block a significant proportion of ADCC-mediating Ab activity detectable in HIV-1-infected individuals (13).

We have recently observed that ADCC-mediating Ab responses are detectable as early as 48 days after acute HIV-1 infection (37). This early appearance of ADCC-mediating Abs after acute HIV-1 infection contrasts with HIV-1 broadly neutralizing antibodies (bNAbS) that appear approximately 2 to 4 years after HIV-1 infection (16, 27, 42).

In this study, we have defined a series of modestly somatically mutated ADCC-mediating antibodies induced by the ALVAC-HIV/AIDSvAX B/E vaccine (34, 39), most of which are directed against conformational A32-blockable epitopes of the gp120 en-
veloped glycoprotein. This group of antibodies displayed preferential use of the variable heavy 1 (VH1) gene segment, a phenomenon non similar to that recently described for highly mutated CD4 binding-site (CD4bs)-specific bNAbs (41, 52).

**MATERIALS AND METHODS**

Plasma and cellular samples from vaccine recipients. All trial participants gave written informed consent as described for both studies (34, 39). Samples were collected and tested according to protocols approved by the institutional review boards at each site involved in these studies. Plasma samples were obtained from volunteers enrolled in the phase I/II clinical trial (34) and in the community-based, randomized, multicenter, double-blind, placebo-controlled phase III efficacy trial (39); both trials tested the prime-boost combination of vaccines containing ALVAC-HIV (vCP1521) (Sanofi Pasteur) and AIDSVAX B/E (Global Solutions for Infectious Diseases). Plasma samples collected at enrollment (week 0) and 2 weeks after the last immunization (week 26) were selected by simple random sampling with a vaccine/placebo ratio of 40:10 for both men and women.

Peripheral blood mononuclear cells (PBMCs) from six vaccine recipients enrolled in the phase II (n = 3) and phase III (n = 3) trials whose plasma showed ADCC activity were used for isolation of memory B cells and monoclonal antibodies (mAbs). Subjects T141485, T141449, and T143859 participated in the phase II trial; subjects 609107, 210884, and 347759 were enrolled in the phase III trial. All six subjects had negative serology for HIV-1 infection at the time of collection.

**Competition binding assay.** To determine the presence of A32 binding Ab in the plasma of the vaccine recipients, we modified the previously described full-length single-chain (FLSC) assay (9). Briefly, biotinylated A32 was used at a limiting dilution of 0.173 μg/ml to compete for the binding of plasma Ab to a single-chain complex (FLSC) captured (AbD D7324) on a plate. Plasma samples from 80 vaccine recipients and 20 placebo recipients were initially screened at a 1:50 final dilution. For plasma samples that blocked binding of biotinylated A32 MAb, the ability to mediate ≥50% of A32 blocking at 1:50 dilution was used as the criterion for inclusion in this study. Seventy-nine plasma samples met this criterion (data not shown) and were tested in a serial dilution to calculate the 50% inhibitory dose (ID₅₀) titer.

**ADCC-luciferase (ADCC-92TH023) assay.** Plasma was evaluated for ADCC activity against cells infected by HIV-1 92TH023 in an assay that employs a natural killer (NK) cell line as effectors. The NK cell line was derived from KHYG-1 cells (Japan Health Sciences Foundation) (54). These cells were transduced with a retroviral vector to stably express the V158 variant of human CD16a (FCGR3A). The target cells were CEM.NKRCCR5 cells (AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH; contributed by Alexander Trkola) (47), which were modified to express Firefly luciferase upon infection. Target cells were infected with HIV-1 92TH023 by spinoculation (35) 4 days prior to use in assays. NK effectors and 92TH023-infected targets were incubated at an effector/target (E/T) ratio of 10:1 in the presence of triplicate serial dilutions of plasma samples for 8 h. Wells containing NK cells and uninfected targets without plasma defined 0% relative light units (RLU), and wells with NK cells plus infected targets without plasma defined 100% RLU. ADCC activity was measured as the percent loss of luciferase activity with NK cells plus infected targets in the presence of plasma.

**Recombinant gp120 HIV-1 proteins.** Where indicated, CEM. NKRCCR5 target cells were coated with recombinant gp120 HIV-1 protein from the CM243 isolate representing the subtype A/E HIV-1 envelope (GenBank accession no. AY214109; Protein Sciences, Meiden, CT). The optimum amount to coat target cells was determined as previously described (36).

**Virus and IMCs for ADCC GTL assay.** HIV-1 reporter viruses used were replication-competent infectious molecular clones (IMC) designed to encode subtype A/E, B, or C env genes in cis within an isogenic backbone that also expresses the Renilla luciferase reporter gene and preserves all viral open reading frames (10). The Env-IMC-LucR viruses used were subtype A/E NL-LucR.T2A-AC.M235-ecto (IMC_M235) (GenBank accession no. AF259954.1) plasmid provided by Jerome Kim, U.S. Military HIV Research Program, subtype B NL-LucR.T2A-BA.Lecto (IMC_BaL) (1), subtype C NL-LucR.T2A-DU422.ecto (IMC_Du422) (GenBank accession no. DQ411854), and subtype C NL-LucR.T2A-DU151.ecto (IMC_Du151) (GenBank accession no. DQ411851). Reporter virus stocks were generated by transfection of 293T cells with proviral IMC plasmid DNA and titrated on TZM-bl cells for quality control.

**ADCC-GTL assay.** ADCC activity was detected according to our previously described ADCC-GranToxIlux (GTI) procedure (36). We used the following target cells: CM243 gp120 coated (ADCC-CM243 assay) and IMC_CM235+, IMC_BaL+, IMC_Du422+, and IMC_Du151+-infected CEM. NKRCCR5 cells (ADCC-E.CM235, ADCC-B.BaL, ADCC-C.DU422, and ADCC-C.DU151 assay, respectively) (47). All of the PBMC samples from the seronegative donors used as effector cells were obtained according to the appropriate institutional review board protocol. We used 10,000 target cells per well, and E/T ratios of 30:1 and 10:1 were used for whole PBMC and purified NK effector cells, respectively. MAb A32 (James Robinson, Tulane University, New Orleans, LA), palivizumab (MedImmune, LLC, Gaithersburg, MD) used as a negative control), and vaccine-induced MAb were tested as six 4-fold serial dilutions starting at a concentration of 40 μg/ml (range, 40 to 0.039 μg/ml). For the Fab blocking assay, the target cells were incubated for 15 min at room temperature in the presence of 10 μg/ml A32, 19B (31), and 17B (46) Fab fragments, which were produced by Barton Haynes. The excess Fab was removed by washing the target cell suspensions once before plating with the effector cells as previously described (13). A minimum of 2.5 × 10⁴ events representing viable gp120-coated or infected target cells was acquired for each well. Data analysis was performed using FlowJo, v.9.3.2 software. The results are expressed as percent granzyme B (GzB) activity, defined as the percentage of cells positive for proteolytically active GzB out of the total viable target cell population. The final results are expressed after subtracting the background represented by the percent GzB activity observed in wells containing effector and target cell populations in the absence of MAb, IgG preparation, or plasma. The results were considered positive if the percent GzB activity after background subtraction was >8% for the gp120–coated cells or >5% for the CM235–infected target cells.

**Isolation of ADCC-mediating monoclonal antibodies.** Monoclonal antibodies were isolated either from IgG⁺ memory B cells cultured at near clonal dilution for 14 days (4), followed by sequential screenings of culture supernatants for HIV-1 gp120 Env binding and ADCC activity, or from memory B cells that bound to the HIV-1 group M consensus gp140, gp140 envy sorted by flow cytometry (16).

Subject 210884 was tested using IgG⁺ memory B-cell cultures isolated and cultured at near clonal dilutions as previously described (4). Briefly, 57,600 IgG⁺ memory B cells were isolated from frozen PBMCs by selecting CD19⁺, CD14⁻, CD16⁻, CD235a⁺, IgD⁺, and IgG⁺ cells through two rounds of separation with magnetic beads (Miltenyi Biotec, Auburn, CA) and resuspended in complete medium containing 2.5 μg/ml OCP gp160 (t10-206; InvivoGen, San Diego, CA), 5 μM CHK2 kinase inhibitor (Calbiochem/EMD Chemicals, Gibbstown, NJ), and Epstein-Barr virus (EBV; 200 μg/ml of B95-8 cells/10⁶ memory B cells). After overnight incubation in bulk, cells were distributed into 96-well round-bottom tissue culture plates at a cell density of 8 cells/well in the presence of ODN2006, CHK2 kinase inhibitor, and irradiated (7,500 cGy) CD40 ligand-expressing L cells (5,000 cells/well). Cells were refed at day 7 and harvested at day 14.

Subjects T141485, T141449, T143859, and 609107 were tested using antigen-specific memory B-cell sorting as previously described (16), with the following modifications. The group M consensus gp140, gp140/env labeled with Pacific Blue and Alexa fluor 647 (Invitrogen, Carlsbad, CA) was used for sorting. Memory B cells were gated as Aqua vital dye - , CD3⁻, CD14⁻, CD16⁻, CD235a⁻, CD19⁺, and surface IgG⁺; memory B cells
stained with gp140\textsubscript{con,S} in both colors were sorted as single cells as described previously (16). A total of 137,345 memory B cells were screened using this method: 32,766 from subject T141485, 54,621 from subject T141449, 20,629 from subject T143859, and 29,329 from subject 609107.

For subject 347759, memory B cells were screened using both methods: 57,600 cells were cultured at nearly clonal dilution and 69,400 memory B cells were sorted. Sorted cells were previously enriched for IgG+ memory B cells as described above, incubated overnight in complete medium containing 2.5 μg/ml oCpG ODN2006, 5 μM CHK2 kinase inhibitor, and EBV (200 μl supernatant of B95-8 cells/10\textsuperscript{6} memory B cells), and then stimulated for 7 days at a cell density of 1,000 cells/well in the presence of ODN2006, CHK2 kinase inhibitor, and irradiated CD40 ligand-expressing L cells (5,000 cells/well).

**Isolation of V(D)J immunoglobulin regions.** Single-cell PCR was performed as previously described (25, 50). Briefly, reverse transcription (RT) was performed using Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA) and human constant region primers for IgG, IgA\textsubscript{1}, IgA\textsubscript{2}, IgM, IgD, Igk, and Ig\lambda; separate reactions amplified individual V\textsubscript{H}, V\textsubscript{L}, and V\textsubscript{\gamma}, and V\textsubscript{\delta}, families from the cDNA template using two rounds of PCR. Products were analyzed with agarose gels (1.2%) and purified with PCR purification kits (Qiagen, Valencia, CA). Products were sequenced in forward and reverse directions using a BigDye sequencing kit using an ABI 3700 device (Applied Biosystems, Foster City, CA). Sequence base calling was performed using Phred (11, 12); forward and reverse strands were assembled using an assembly algorithm based on the quality scores at each position (32). The estimated PCR artifact rate was 0.28 or approximately one PCR artifact per five genes amplified. Ig isotype was determined by local alignment with genes of known isotype (44); V, D, and J region genes, CDR3 loop lengths, and mutation rates were identified using SoDA (48), and data were annotated so that matching subject data and sort information were linked to the cDNA sequence and analysis results.

**Expression of recombinant antibodies.** Isolated Ig V(D)J gene pairs were assembled by PCR into linear full-length Ig heavy- and light-chain gene expression cassettes (25) and optimized as previously described for binding to the Fcy receptors (43). Human embryonic kidney cell line 293T (ATCC, Manassas, VA) was grown to near confluence in 6-well tissue culture plates (Becton Dickson, Franklin Lakes, NJ) and transfected with 2 μg per well of purified PCR-produced IgH and IgL linear Ig gene expression cassettes using Effectene (Qiagen). The supernatants were harvested from the transfected 293T cells after 3 days of incubation at 37°C in 5% CO\textsubscript{2}, and the monoclonal antibodies were purified as previously described (25).

**Direct binding ELISAs.** Three hundred eighty-four-well plates (Corning Life Sciences, Lowell, MA) were coated overnight at 4°C with 15 μl of purified HIV-1 monomer gp120 envelope glycoprotein (E.A244 gp120, B.MN gp120, and A.92TH023 gp120) antigen at 2 μg/ml and blocked with assay diluent (phosphate-buffered saline [PBS] containing 4% [wt/vol] whey protein–15% normal goat serum–0.5% Tween 20–0.05% sodium azide) for 1 h at room temperature.

Ten μl/well of purified MAbS was incubated for 2 h at room temperature in serial 3-fold dilutions starting at 100 μg/ml for the determination of 50% effective concentrations (EC\textsubscript{50}) and then washed with PBS–0.1% Tween 20. Thirty μl/well of alkaline phosphatase-conjugated goat anti-human IgG in assay diluent was added for 1 h, washed, and detected with 30 μl/well of p-nitrophenyl phosphate substrate diluted in 50 mM NaHCO\textsubscript{3} plus NaCO\textsubscript{3} (1:1, vol/vol), pH 9.6, 10 mM MgCl\textsubscript{2}. Plates were developed for 45 min in the dark at room temperature and read at an optical density of 405 nm (OD\textsubscript{405}) with a VersaMax microplate reader ( Molecular Devices, Sunnyvale, CA).

Epitope mapping studies were performed using 15-mer linear peptides spanning the gp120 envelope glycoprotein of the MN and 92TH023 HIV-1 strains obtained from the AIDS Reagent Repository as coating antigens, horseradish peroxidase goat anti-human IgG as secondary antibody, and 3,3',5,5'-tetramethylbenzidine (TMB) substrate for detection.

---

**RESULTS**

**Vaccine-induced ADCC responses.** We studied 50 simple randomly sampled plasma specimens drawn from subjects enrolled in the RV144 vaccine trial at enrollment (week 0) and 2 weeks after the last immunization (week 26), including 10 placebo recipients (5 male and 5 female) and 40 vaccine recipients (20 male and 20 female; four injections of recombinant canarypox vector vaccine ALVAC-HIV [vCP1521] and two booster injections of recombinant gp120 subunit [AIDSVAX B/E]) (34, 39). The frequency of ADCC responders (Table 1) and the AUC for ADCC activity (Fig. 1A to D) of both vaccine and placebo recipients were measured using two ADCC assays, CEM.NKR\textsubscript{CCR5} target cells either coated with HIV-1 AE.CM243 gp120 (ADCC-CM243) (36) or infected with the AE.92TH023 HIV-1 strain (ADCC-92TH023) (17).

The ADCC response rate measured with the ADCC-CM243 assay increased from 0% at week 0 to 90% at week 26 among the vaccine recipients (Table 1). Similarly, the ADCC-92TH023 assay detected activity in 72.5% (29/40) of vaccine recipients at week 26 (Table 1). For both assays, the frequency of positive responses among the vaccine recipients was significantly higher comparing baseline (week 0) to postimmunization (week 26) (P < 0.0001 for both assays).

---

**TABLE 1 Frequency of ADCC responders among vaccine and placebo recipients before and after vaccination**

| Recipient group | Assay result (no. of responders [% CI]) |
|-----------------|----------------------------------------|
| Vaccine (40)    |                                        |
| Wk 0            | 0 (0, 0–31)                            |
| Wk 26           | 36 (90, 76–97)                         |
| Placebo (10)    |                                        |
| Wk 0            | 1 (10, 0–44.5)                         |
| Wk 26           | 1 (10, 0–44.5)                         |

---

**Statistical analyses.** The analysis of the ADCC-mediated Ab responses in the plasma of the vaccine recipients was conducted as follows. For each time point of a subject, partial area under the activity versus the log10 (dilution) curve (AUC) was estimated nonparametrically for each assay. For ADCC-CM243 assay using gp120-coated target cells, the AUC was calculated based on percent GzB activity across dilution levels of 50, 250, 1,250, 6,250, 31,250, and 156,250; for ADCC-92TH023 assay using infected cells, the AUC was calculated based on percent loss of luciferase activity across dilution levels of 32, 100, 316, and 1,000. Two-sample t test allowing for unequal variance was used to test the mean difference in AUC between the vaccine and placebo groups at week 26. A paired t test was used to test the mean difference in AUC between week 26 and week 0 among vaccinees. For each of the vaccine and placebo groups and for each time point, the positive response rate was estimated by the observed fraction of subjects that have a positive response (defined as peak percent GzB greater than 8% for the ADCC-CM243 assay and peak percent loss of luciferase activity greater than 9% for the ADCC-92TH023 assay). A 95% confidence interval (CI; computed by the Agresti-Coull method) was provided around each response rate. An exact P value from McNemar’s test was used to evaluate whether the response rate differs for the week 26 time point versus the week 0 time point among vaccinees. Fisher’s exact test was used to provide a P value to test whether the response rate differed between the vaccine and placebo groups at week 26.

The other statistical analyses conducted in this study were performed using Prism software v5.0c (GraphPad Software, Inc.), and the appropriate methods are listed throughout the manuscript.

---

**Number 21**

November 2012 Volume 86 Number 21 jvi.asm.org

11523

Characterization of HIV-1 Vaccine-Induced ADCC Abs

Downloaded from http://jvi.asm.org on July 23, 2018 by guest
immune correlate primary analysis, and in the secondary analysis, the 92TH023-infected target cell ADCC assay was used in the RV144 studies as well as in RV144 (17,21). It is important to note that the among vaccinees is similar to that reported in earlier phase II ents depending on the assay utilized. This frequency of responders ti-HIV-1 gp120 ADCC activity in to D). Thus, the ALVAC-HIV/AIDSVAX B/E vaccine induced an-
group at week 26 ( \( P \) to H9262). Plasma samples were collected at week 26 from 30 vaccine recipients and were tested at dilutions corresponding to peak activity. Data are reported as maximum percent G\( \delta \)B activity detected using CM243-gp120-coated targets without pretreatment (no Fab pretreatment; left) or treated with 10 \( \mu \)g/ml MAb A32 Fab (center) or palivizumab Fab (negative control; right). Lines and error bars represent the mean percent G\( \delta \)B activity ± SD. The P values were obtained using repeated-measure analysis of variance. pos, positive; neg, negative; n.s., not significant.

We next evaluated the AUC of a dilution of antibody in the assay (see the statistical analysis in Materials and Methods). In both the ADCC-CM243 and ADCC-92TH023 assays, AUC values of vaccinated subjects at week 26 were significantly higher than both of those in the vaccine recipients at week 0 and in the placebo group at week 26 ( \( P < 0.0001 \) and \( P < 0.001 \), respectively) (Fig. 1A to D). Thus, the ALVAC-HIV/AIDSVAX B/E vaccine induced anti-HIV-1 gp120 ADCC activity in ~70 to 90% of vaccine recipients depending on the assay utilized. This frequency of responders among vaccinees is similar to that reported in earlier phase II studies as well as in RV144 (17,21). It is important to note that the 92TH023-infected target cell ADCC assay was used in the RV144 immune correlate primary analysis, and in the secondary analysis, high activity in this assay associated with low plasma anti-Env IgA responses inversely correlated with infection risk (17).

**Plasma ADCC activity is blocked in part by MAB A32.** Since MAB A32 can block plasma ADCC responses during chronic infection (13), we sought to determine whether A32-like antibodies were produced by RV144 vaccine recipients. We first evaluated the ability of plasma samples collected at week 26 postvaccination from simple random samples drawn from both RV144 vaccine ( \( n = 79 \) out of 80; one sample was not studied because of less than 50% inhibition at screening) and placebo ( \( n = 20 \) ) recipients for their ability to block the binding of biotinylated A32 MAb to B.BaL Env. Plasma Ab blocked A32 MAb binding in 76/79 (96.2%) of the vaccine recipients with an average 50% inhibitory dose (ID\(_{50}\) ) titer of 119 (95% CI, 95 to 130) (Fig. 2A). These data demonstrated the presence of A32-like antibodies in the plasma of vaccine recipients.

We then evaluated the effect of pretreatment of CM243 gp120-coated target cells with A32 Fab on plasma-mediated ADCC (13). Thirty vaccine recipients whose plasma samples were previously identified to mediate ADCC were selected to represent each tertile (low, medium, and high response) of the range of ADCC activities observed. These plasma samples were tested to determine the di-
lution that provided maximum ADCC activity (data not shown). When tested at the optimal dilution, these plasma samples induced granzyme B (G\( \delta \)B) activity against AE.CM243 gp120-coated target cells ranging from 8.0 to 34.6% (mean ± standard deviation [SD], 20.4 ± 6.6) (Fig. 2B). When the cells were pre-
treated with 10 \( \mu \)g/ml of A32 Fab, ADCC activity was reduced or completely abrogated for each plasma sample (G\( \delta \)B activity, ≤3.2%; \( P < 0.001 \) versus untreated samples) (Fig. 2B). Similar treatment with a control Fab made from palivizumab (19) did not affect plasma ADCC activity (range, 9.0 to 35.8%; mean ± SD, 21.1% ± 6.7%) (Fig. 2B). However, preincubation with 10 and 50 
\( \mu \)g/ml of A32 Fab did not block plasma ADCC activity at the peak of responses (1:50 dilution) in ADCC assays using target cells infected with either the E.92TH023 or the E.CM235 HIV-1 strains (data not shown). This lack of inhibition may be due to unfavorable kinetics for Fab epitope recognition on infected cells in the
presence of polyclonal antibodies in plasma. To better define the nature of the antibodies responsible for the observed ADCC activity, we isolated ADCC-mediating MAbs from ALVAC-HIV/AIDSVAX B/E vaccine recipients.

**Isolation of ADCC-mediating antibodies from ALVAC-HIV/AIDSVAX B/E vaccines.** We isolated a total of 23 MAbs that mediated ADCC from memory B cells of six vaccine recipients enrolled in the RV135 phase II \((n = 3)\) (21, 34) or RV144 phase III \((n = 3)\) (39) ALVAC-HIV/AIDSVAX B/E clinical trials. Nine MAbs (CH49, CH51, CH52, CH53, CH54, CH55, CH57, CH58, and CH59) were obtained from cultured IgG-positive memory B cells that bound to one or more of the E.A244, B.MN, and E.92TH023 gp120 envelope glycoproteins, while the remaining 14 were obtained from group M consensus gp140\textsubscript{Con,S} Env-specific flow-cytometric single-memory-B-cell sorting (4, 16). Two of the 23 ADCC-mediating MAbs were against the gp120 Env V2 region and are the subject of a separate report (H.-X. Liao, M. Bon-signori, B. F. Haynes, unpublished data).

ADCC activity of the remaining 21 MAbs, purified and expressed in a codon-optimized IgG1 backbone, was measured using both E.CM243 gp120-coated (ADCC-CM243) and E.CM235-infected (ADCC-CM235) target cells in the flow-based assay described in Materials and Methods. The maximum percent GzB activity of the 21 MAbs ranged from 38.9% (CH54) to 6.0% (CH92) (Fig. 3A). Remarkably, 11/21 MAbs displayed a maximum percent GzB activity greater than that of A32 MAb (16%) in duplicate assays: CH54 (38.9%), CH55 (31.4%), CH57 (31.3%), CH23 (31.2%), CH49 (26.7%), CH51 (25.9%), CH53 (24.4%), CH52 (23.9%), CH40 (22.6%), and CH20 (21.0%). The endpoint titers of each of the 21 MAbs (Fig. 3B) ranged from <20 ng/ml to 30.3 μg/ml (means ± SD, 4.1 ± 8.8 μg/ml).

None of the ADCC-mediating MAbs were heavily somatically mutated: the mean nucleotide mutation frequencies of the heavy and light chains were 2.4% (range, 0.5 to 5.1%) and 1.8% (range, 0.4 to 4.3%), respectively (Table 2). These data demonstrate that the ALVAC-HIV/AIDSVAX B/E vaccine induced polyclonal antibody responses capable of mediating moderate to high levels of ADCC activity without requiring high levels of ADCC antibody affinity maturation.

**Epitope mapping of vaccine-induced ADCC-mediating antibodies.** To define the specificity of ADCC-mediating MAbs, we asked if they recognized linear epitopes by testing their ability to bind to overlapping linear peptides spanning the gp120 envelope glycoprotein of the B.MN or E.92TH023 HIV-1 strain. Each MAb bound to one or more of the vaccine gp120 envelope glycoproteins, which included the B.MN and E.92TH023 strains (Table 3). We found that 19/20 MAbs (CH53 was not tested) did not react with any of the B.MN or E.92TH023 peptides, while one (CH23) reacted with the clade E V3 loop (NTRTSINIGRGQVFY). As previously described, we used the A32 Fab blocking strategy in the ADCC-CM235 assay to determine whether the ADCC activity of the 20 MAbs not specific for the V3 loop was mediated by target-cell conformational epitopes expressed on infected cells that could be blocked by the A32 MAb (Fig. 4). As a control, we also tested the ability of these 20 MAbs to block the ADCC activity mediated by 17B and 19B Fab fragments, which target the CD4-induced (CD4i) and V3 epitopes, respectively (Fig. 4). In contrast to plasma ADCC activity, which could not be blocked by A32 when tested against CM235-infected target cells, A32 Fab blocking inhibited between 73 and 100% (means ± SD, 92% ± 9%) of the ADCC activity mediated by 19/20 (95%) non-V3 MAbs (Fig. 4). CH20 was not inhibited by any of the A32, 17B, or 19B Fab fragments (Fig. 4). None of the MAbs displayed substantial loss of ADCC activity (defined as >20% inhibition) when E.CM235-infected target cells were preincubated with Fab fragments of MAb 17B or 19B (Fig. 4).

To confirm the results observed with the ADCC assay, we tested the ability of the ADCC-mediating MAbs to block A32 binding to the AE.A244 gp120 envelope glycoprotein and found that 16 MAbs blocked 20.7 to 94% of A32 binding to gp120 Env (Fig. 5). As expected, MAb CH20 did not block MAb A32 binding to gp120 Env, consistent with the inability of A32 Fab to block CH20-meditated ADCC activity. Of note, CH29 and CH57 did not reciprocally block A32 binding to the envelope, even though A32 Fab blocked their ADCC activity (Fig. 4) and MAb A32 blocked their binding to Env (Table 3).
TABLE 2 Characteristics of the V(D)J rearrangements of vaccine-induced ADCC-mediating monoclonal antibodies

| PTIDa | MAb | Isotype | V     | D     | J     | CDR3b | Mutation frequencyc (%) | Type | V | I  | CDR3b | Mutation frequencyc (%) |
|-------|-----|---------|-------|-------|-------|-------|-------------------------|------|---|----|-------|-------------------------|
| T141485 | CH20 | G1      | 1-69*02 | 6-6*01 | 4*02  | 15    | 2.6                     | λ    | 2-23*02 | 3*02 | 10      | 0.4                         |
| T141449 | CH23 | G1      | 1-2*02  | 2-OF15*02 | 6*02 | 12    | 2.3                     | λ    | 4-1*01 | 4*01 | 8      | 0.8                         |
| CH89   | G3   | 1-2*02  | 3-22*02 | 4*02  | 15    | 2.1                     | λ    | 1-39*01 | 4*01 | 9      | 1.4                         |
| CH92   | G1   | 1-2*02  | 2-15*01 | 4*02  | 19    | 1.7                     | λ    | 1D-12*01 | 5*01 | 9      | 2.6                         |
| CH80   | G1   | 1-2*02  | 1-IR1*01C | 4*02 | 12    | 1.6                     | λ    | 1-27*01 | 4*01 | 10     | 1.1                         |
| CH29   | A2   | 1-2*02  | 2-15*01 | 4*02  | 19    | 0.8                     | λ    | 1-39*01 | 4*01 | 9      | 0.6                         |
| CH78   | G1   | 1-2*02  | 3-22*01 | 4*02  | 19    | 0.7                     | λ    | 3-11*01 | 1*01 | 9      | 1.1                         |
| CH94   | G1   | 1-46*02 | 5-12*01 | 6*02  | 14    | 2.2                     | λ    | 1-39*01 | 2*01 | 9      | 1.7                         |
| CH90   | G1   | 1-46*01 | 3-10*01 | 4*02  | 14    | 1.5                     | λ    | 1-13*02 | 1*01 | 9      | 4.3                         |
| CH91   | G1   | 4-31*03 | 4-17*01 | 3*02  | 15    | 2.0                     | λ    | 2-11*01 | 3*02 | 11     | 1.4                         |
| CH23   | G1   | 3-66*01 | 3-OR15*3 | 1*01 | 11    | 4.5                     | λ    | 6-57*01 | 3*02 | 10     | 2.2                         |
| 609107 | CH81 | G1      | 1-8*01  | 3-10*01 | 4*02  | 19    | 0.5                     | λ    | 1-39*01 | 2*01,02 | 9  | 1.4                         |
| CH40   | G1   | 1-46*02 | 6-6*01  | 5*02  | 15    | 3.6                     | λ    | 3-20*01 | 4*01 | 5      | 0.9                         |
| CH49   | G1   | 1-2*02  | 1-26*01 | 4*02  | 16    | 5.1                     | λ    | 2-11*01 | 3*02 | 10     | 3.1                         |
| CH53   | G1   | 1-2*02  | 2-20*01,02 | 4*02 | 16    | 2.3                     | λ    | 2-11*01 | 2*01 | 10     | 2.4                         |
| CH52   | G1   | 1-2*02  | 6-13*01 | 4*02  | 13    | 1.4                     | λ    | 3-20*01 | 2*01 | 10     | 1.8                         |
| CH55   | G1   | 1-46*01 | 1-11*01 | 5*02  | 15    | 4.3                     | λ    | 3-15*01 | 5*01 | 10     | 1.5                         |
| CH54   | G1   | 1-58*02 | 1-26*01 | 5*02  | 14    | 2.1                     | λ    | 1-39*01 | 2*01 | 9      | 1.4                         |
| CH51   | G1   | 4-34*12 | 3-10*01 | 4*02  | 14    | 0.5                     | λ    | 3-20*01 | 1*01 | 8      | 0.6                         |
| 347759 | CH57 | G1      | 1-2*02  | 1-1*01  | 6*02  | 12 | 3.4 | λ | 1-39*01 | 1*01 | 9 | 4.0 |
| CH38   | A1   | 3-23*01 | 3-10*01,02 | 1*01 | 12 | 4.7 | λ | 2-14*03 | 3*02 | 10 | 3.6 |

a PTID, participant identity.

b CDR3, complementarity determining region 3. Length is expressed as amino acids according to the Kabat numbering system (20).

c Nucleotide mutation frequency in V gene as determined by SoDA (48).

We found that 6/19 (32%) of the A32-blockable MAbs partially blocked the binding of soluble CD4 (sCD4) and/or MAb b12 to gp120 envelope glycoproteins (Table 3). This activity ranged from 22% (CH77) to 47% (CH40) of cd40 binding to AE.A244 gp120 Env and from 25% (CH40) to 40% (CH55) blocking of b12 binding to B.JRFL gp120 Env; in some cases blocking was higher than that seen for A32 (Table 3). These data suggest that these ADCC-mediating MAbs interfere with binding of CD4bs-directed MAbs either by inducing conformational changes on the gp120 envelope glycoprotein or by partially blocking access to the CD4bs. The combination of blocking and binding data indicate that the RV144 immunogen elicited a diverse set of antibodies directed at epitopes overlapping, but not identical to, that of MAb A32.

**VH1 gene family members are overrepresented among ADCC-mediating monoclonal antibodies recovered from vaccine recipients.** Association of anti-HIV-1 ADCC activity with the use of a specific VH family gene has not been previously reported. It was therefore quite surprising to find that 17/23 (74%) of the 23 ADCC-mediating monoclonal antibodies recovered from vaccinees from different HIV-1 subtypes. MAb A32 mediated ADCC against all four tested isolates with an endpoint titer of 0.039 μg/ml against all strains (Fig. 6). Each of the 21 MAbs derived from vaccinees were able to mediate ADCC against target cells infected with the subtype A/E strain virus AE.CM235, while 14/21 MAbs (67%) mediated ADCC against those infected with B.Bal. When tested against subtype C virus isolates, 4/21 (19%) of the 21 MAbs mediated ADCC against C.DU151-infected target cells while a single recovered MAb (CH54) mediated ADCC against C.DU422-infected target cells (Fig. 6). The patterns of cross-clade ADCC activity, combined with the patterns observed in binding and blocking experiments, demonstrate that the RV144 immunogen elicited a diverse set of antibodies directed at epitopes overlapping, but not identical to, that of MAb A32.
The frequency of VH1 gene usage among vaccine-induced HIV-specific ADCC-mediating antibodies also was higher than those of other published data sets: in HIV-1-negative subjects, Brezinschek and colleagues reported the frequency of VH1 genes to be approximately 13% (9/71 reported in reference 6; \( P = 0.0001 \) by Fisher’s exact test comparing the ADCC-mediating antibodies), while in chronically HIV-1-infected subjects the frequency of VH1 usage in anti-HIV-1 antibodies was reported to be 39% (76/193 reported in reference 5; \( P = 0.003 \) by Fisher’s exact test comparing the ADCC-mediating antibodies). We have recently reported frequencies of HIV-1 reactive antibodies using VH1 gene segments of 16.4% (11/67) in HIV-1 acutely infected subjects, which is similar to VH1 usage reported in the National Center for Biotechnology Information database (15.2%; 5,238/34,384) (24), and 38.2% (13/34) in vaccine recipients enrolled in an unrelated HIV-1 vaccine trial (29). In both cases, the frequency of VH1 gene segment usage in ALVAC-HIV/AIDSvAX B/E-induced ADCC-mediating antibodies was significantly higher (\( P < 0.0001 \) and \( P = 0.014 \), respectively, by Fisher’s exact test). In the present study, none of the recovered ADCC antibodies were clonally related, and VH1 antibodies were recovered from 5/6 vaccinees studied. Thus, the high frequency of usage of VH1 heavy-chain genes among antibodies that mediate ADCC suggests that B cells using those genes have been preferentially selected by the vaccine trial Env proteins.

It is possible that this phenomenon relates to properties of gp120 more generally. Analysis of a different HIV-1 vaccine trial resulted in the recovery of 13/34 (38%) MAbs that used VH1 genes, including 2 MAbs with ADCC activity and 1 with neutralizing activity (29). In contrast, only 12/252 (5%) influenza virus-specific antibodies recovered after influenza immunization (30) used VH1 genes.

ADCC activity of antibodies using VH1 genes correlated with the degree of somatic mutation. A number of recent studies have suggested that highly somatically mutated anti-CD4bs bNAbs preferentially use the VH1 gene, in particular the VH 1-2*02 and 1-46 segments, and common amino acid sequence

### TABLE 3

| PTIDa and MAb | Bindingb of MAbs to HIV-1 Env | % Blocking by MAb | sCD4 binding to | sCD4 binding to | b12 binding to |
|--------------|-----------------------------|------------------|----------------|----------------|----------------|
|              | A244 gp120                  | 92TH023 gp120    | MN gp120       | A244 gp120     | JRFL gp120     |
| T141485      |                             |                  |                |                |                |
| CH20         | –                           | ++               | ++             | –              | –              |
| T141449      |                             |                  |                |                |                |
| CH77         | ++                          | +++              | +++            | 22             | –              |
| CH80         | +                           | –                | ++             | –              | –              |
| CH89         | –                           | –                | +              | –              | –              |
| CH92         | –                           | –                | ++             | –              | –              |
| CH80         | +                           | –                | ++             | –              | –              |
| CH78         | ++                          | +++              | ++             | –              | –              |
| CH94         | +++                         | +                | +++            | –              | –              |
| CH90         | –                           | –                | +++            | –              | –              |
| CH91         | ++                          | +++              | ++             | –              | –              |
| CH23         | +++                         | +++              | +++            | 36             | –              |
| T143859      |                             |                  |                |                |                |
| CH23         | +                           |          | ++            | 46             | 20             |
| CH81         | –                           | –                | ++            | –              | –              |
| CH40         | +++                         | ++              | +++            | –              | –              |
| 210884       |                             |                  |                |                |                |
| CH94         | +++                         | –                | –              | –              | –              |
| CH95         | +++                         | +                | ++            | –              | –              |
| CH92         | +++                         | +                | +++            | 32             | –              |
| CH95         | +                           | –                | ++            | 31             | –              |
| CH94         | +                           | –                | ++            | –              | –              |
| CH91         | +                           | –                | ++            | –              | –              |
| 347759       |                             |                  |                |                |                |
| CH57         | –                           | +++              | +++            | –              | –              |
| CH38         | +++                         | +++              | +++            | –              | –              |
| Controls     |                             |                  |                |                |                |
| A32          | 29                          | –                | 23             | –              | –              |
| Palivizumab  | –                           | –                | –              | –              | –              |
| VRC-CH31     | 97                          | 67              | 70             | –              | –              |

a PTID, participant identity.
b ++++, 50% inhibitory concentration (IC50) of <10 nM; +++, IC50 between 10 and 100 nM; +, IC50 between 0.1 and 1 \( \mu \)M; –, negative/no binding/no blocking.
motifs (HAAD motifs) have been described for both the heavy and light chains of such anti-CD4bs bNAbs (41, 51). It was striking that among the ADCC-mediating VH1 antibodies that we recovered, 10/17 (59%) used the VH1-2*02 gene segment (Fig. 7). None of the MAbs recovered from this group of participants had broad neutralizing activity, and of the MAbs reported here, only the V3-specific MAb CH23 (VH3-66) displayed tier 1 strain-specific neutralizing activity (28). We sought to determine if this group of antibodies shared the previously described HAAD motifs with the potent CD4bs bNAbs (41). Alignments of the amino acid sequences of the 17 vaccine-induced ADCC-mediating antibodies that used VH1 with the heavy- and light-chain HAAD consensus motifs showed a high degree of similarity (range, 46 to 57 matching amino acids [aa] of 68 aa for the heavy chain, 68 to 84%, and 37 to 46 matching aa of 53 aa for the light chain, 70 to 87%) (Fig. 8A, red circles), which was comparable to the levels of similarity of the CD4bs bNAbs (Fig. 8A, black crosses). We also analyzed a group of three non-HIV-1-reactive VH1-2 anti-influenza virus antibodies that mediate broad influenza virus neutralization (49), which showed a similar degree of heavy-chain homology (52 to 55 matching aa, 76 to 81%) but less homology for the light chain (31 to 32 matching aa, 58 to 60%) (Fig. 8A, blue diamonds). Thus, the similarity of the RV144 vaccine-induced antibodies to the HAAD motif may not reflect functional selection but rather similarities in Env selection of B cells with similar heavy- and light-chain pairings.

Since the broadly neutralizing CD4bs antibodies are also highly mutating, we sought to determine if the degree of somatic mutation in the RV144-induced antibodies correlated with function. We found that the ability to block sCD4 binding did not correlate with the degree of somatic mutation (Fig. 8B). In contrast, the overall strength of ADCC activity, as measured by maximal percent GzB activity against CM235-infected CD4+ T cells, did correlate with heavy-chain somatic mutation (Spearman correlation, \( r = 0.56; P = 0.02 \)) (Fig. 8B).

**DISCUSSION**

The induction of neutralizing antibody (NAb) and cytotoxic T-lymphocyte (CTL) responses are key goals for HIV-1 vaccine de-
development. Recently, the phase III efficacy trial of the prime-boost combination of vaccines containing ALVAC-HIV and AIDSVAX B/E has offered the first evidence of vaccine-induced partial protection in humans (39). The vaccine appeared to induce NAb responses with a narrow specificity profile and minimal CD8\(^+\) CTL responses (39), suggesting that nonneutralizing Ab and cellular responses other than those of CD8\(^+\) CTL have played a role in conferring protection.

A number of studies have suggested that ADCC play an important role in the control of SIV and HIV-1 infection. Several studies have shown that the magnitude of ADCC Ab responses correlates inversely with virus set point in acute SIV infection in both unvaccinated macaques (45) and in vaccinated animals after infection (2, 7, 14, 15). In humans, ADCC-mediating Abs have been shown to protect against HIV-1 infection in mother-to-infant transmission (26, 33) and to correlate with both control of virus replication (22) and lack of progression to overt disease (3). In contrast, weakly neutralizing and nonneutralizing antibodies were shown to not protect against vaginal simian-human immunodeficiency virus (SHIV) challenge in macaques (8).

ADCC is one of the mechanisms that might have conferred protection from infection in RV144 (17). For this reason, we sought to isolate MAbs that can mediate ADCC from ALVAC-HIV/AIDSVAX B/E vaccine recipients and determine their specificity, clonality, and maturation. In this study, we have demonstrated that the ALVAC-HIV/AIDSVAX B/E vaccine elicited antibodies that mediate ADCC in the majority of the vaccinated subjects, which is in line with previous observations (17, 21), and that gp120 C1 region-specific A32-like antibodies significantly contributed to the overall ADCC responses. By isolating 23 ADCC-mediating MAbs from multiple vaccine recipients, we also demonstrated the presence of ADCC-mediating MAbs of additional specificities. In addition, we determined that the ADCC-mediating MAbs underwent limited affinity maturation and preferentially used VH1 gene segments.

Antibody responses that mediate ADCC were directed toward A32-blockable conformational epitopes (\(n = 19\)), a non-A32-blockable conformational epitope (\(n = 1\)), the gp120 Env V2 region (\(n = 2\)) (23), and a linear epitope in the gp120 V3 region (\(n = 1\)). The conformational epitope recognized by the A32 MAb is a dominant target of HIV-1-positive plasma ADCC antibodies (13), and A32-like MAbs are among the anti-HIV-1 CD4\(\alpha\) Ab responses that are detected following HIV-1 transmission (38, 40). The identification of A32-like MAbs in vaccine recipients suggests that the gp120 epitope recognized by the A32 MAb is an immunodominant region not just in response to natural infection but also upon vaccination. Our data suggest that this A32-binding region reacts with antibodies that have a diverse binding profile, suggesting that the RV144 vaccine targeted multiple related but distinct conformational epitopes on gp120. These epitopes have been shown to be upregulated on the RV144 immunogen and to be efficiently presented by novel Env designs (S. M. Alam, unpublished data), thus it will be possible to test this vaccine strategy in future vaccine trials targeted to different HIV-1 subtypes.

In contrast to ADCC-mediating antibodies, HIV-1 bNAb responses have been reported to appear an average of 2 to 4 years after HIV-1 transmission (16, 27, 42), suggesting that different levels of Ab
maturation are required to mediate ADCC and neutralizing activities. Indeed, the mutation frequencies observed in the MAbs isolated during RV144 or Env gp120 proteins in general preferentially induce the use of the VH1 heavy-chain gene family, which has been previously reported for CD4bs-directed broadly neutralizing antibodies. This observation raises the possibility that continued boosting with this vaccine formulation leads to further somatic mutations of VH1 gp120-specific antibodies and, perhaps, to an enhanced ability to augment any protective effect they might have had to limit HIV-1 acquisition.

ACKNOWLEDGMENTS

We thank Robert J. Parks, Krissey E. Lloyd, Bradley Lockwood, Mark Drinker, Lawrence Armand, Joshua Eudailey, Neil Meguid, Brandy Ward, and Faraha Brewer for excellent technical assistance. We also thank the following members of the Thai AIDS Vaccine Evaluation Group: (i) from AFRIMS, N. Sirisopana, S. Sukwit, S. Tabbrast, A. Kleeboonthala, V. Kamonsin, P. Panjapornphuk, S. Akapirat, W. Kanechit, C. Chuenchitra, P. Chantabuncher, W. Lokpicaht, R. Paris, B. Merrell, J.-L. Exler, S. Wongkamhaeng, A. Triampon, P. Buapunth, S. Chinaworapong, R. Trichavaroj, S. Chantakulkij, N. Khaochalod, S. Mason, P. Srisaengchait, S. Chanthong, Y. Poangngern, and A. Brown; (ii) from the Vaccine Trials Centre, Mahidol University, W. Supamaranond, S. Nakrisuk, W. Peonim, N. Thantamun, and R. Muanoum; (iii) from Siriraj Hospital, Prasert Thongcharoen; and (iv) from the Research Institute of Health Sciences, Chiang Mai University, Vinai Suriyanon.

The views expressed in this article are those of the authors and do not reflect the official policy of the Department of the Army, Department of Defense, or the U.S. Government.

This work was supported by the National Institutes of Health (NIH), National Institutes of Allergies and Infectious Diseases (NIAID), the Division of AIDS with the Center for HIV/AIDS Vaccine Immunology (CHAVI) (grant U19 AI067854); by a Collaboration for AIDS Vaccine Discovery (CAVD) grant to B.F.H. from the Bill and Melinda Gates Foundation; in part by Interagency Agreement Y1-AL-2642-12 between U.S. Army Medical Research and Materiel Command (USAMRMC) and the NIAID. In addition, this work was supported by a cooperative agreement.
REFERENCES
1. Adachi A, et al. 1986. Production of acquired immunodeficiency syn-
drome-associated retrovirus in human and nonhuman cells transfected
with an infectious molecular clone. J. Virol. 59:284–291.
2. Barouch DH, et al. 2012. Vaccine protection against acquisition of neu-
ralization-resistant SIV challenges in rhesus monkeys. Nature 482:89–93.
3. Baum LL, et al. 1996. HIV-1 gp120-specific antibody-dependent cell-
mediated cytotoxicity correlates with rate of disease progression. J. Immun-
ol. 157:2168–2173.
4. Bonsignori M, et al. 2011. Analysis of a clonal lineage of HIV-1 envelope
V2/V3 conformational epitope-specific broadly neutralizing antibodies
and their inferred unmutated common ancestors. J. Virol. 85:9989–
10009.
5. Breden F, et al. 2011. Comparison of antibody repertoires produced by
HIV-1 infection, other chronic and acute infections, and systemic auto-
mune disease. PLoS One 6:e16857. doi:10.1371/journal.pone.0016857.
6. Brezinski HP, Brezinski RI, Lipsky PE. 1995. Analysis of the heavy
chain repertoire of human peripheral B cells using single-cell polymerase
chain reaction. J. Immunol. 155:190–202.
7. Brocca-Cofano E, et al. 2011. Vaccine-elicited SIV and HIV envelope-
specific IgA and IgG memory B cells in rhesus macaque peripheral blood
correlate with functional antibody responses and reduced viremia. Vac-
cine 29:3310–3319.
8. Burton DR, et al. 2011. Limited or no protection by weakly or nonneu-
tralizing antibodies against vaginal SHIV challenge of macaques com-
pared with a strongly neutralizing antibody. Proc. Natl. Acad. Sci. U. S. A.
108:11181–11186.
9. DeVico A, et al. 2007. Antibodies to CD4-induced sites in HIV gp120
 correlate with the control of SHIV challenge in macaques vaccinated with
subunit immunogens. Proc. Natl. Acad. Sci. U. S. A. 104:17477–17482.
10. Edmonds TG, et al. 2010. Replication competent molecular clones of
HIV-1 expressing Renilla luciferase facilitate the analysis of antibody in-
hibition in PBMC. Virolology 408:1–13.
11. Ewing B, Green P. 1998. Base-calling of automated sequencer traces us-
ing phred. II. Error probabilities. Genome Res. 8:186–194.
12. Ewing B, Hillier L, Wendl MC, Green P. 1998. Base-calling of automated
sequencer traces using phred. I. Accuracy assessment. Genome Res. 8:175–
185.
13. Ferrari G, et al. 2011. A HIV-1 gp120 envelope human monoclonal antibody
that recognizes a CI conformational epitope mediates potent
ADCC activity and defines a common ADCC epitope in human HIV-1
serum. J. Virol. 85:7029–7036.
14. Florese RH, et al. 2009. Contribution of nonneutralizing vaccine-elicited
antibody activities to improved protective efficacy in rhesus macaques
immunized with Tat/Env compared with multigenic vaccines. J. Immunol.
182:3718–3727.
15. Gómez-Roman VR, et al. 2005. Vaccine-elicited antibodies mediate an-
tibody-dependent cellular cytotoxicity correlated with significantly re-
duced acute viremia in rhesus macaques challenged with SIVmac251. J.
Immunol. 174:2185–2189.
16. Gray ES, et al. 2011. Isolation of a monoclonal antibody targeting the
alpha-2 helix of gp120 representing the initial autologous neutralizing
antibody response in an HIV-1 subtype C infected individual. J. Virol.
85:7719–7729.
17. Haynes BF, et al. 2012. Immune-correlates analysis of an HIV-1 vaccine
efficacy trial. N. Engl. J. Med. 366:1275–1286.
18. Hidajat R, et al. 2009. Correlation of vaccine-elicited systemic and mu-
cosal nonneutralizing antibody activities with reduced acute viremia fol-
lowing intrarectal simian immunodeficiency virus SIVmac251 challenge
of rhesus macaques. J. Virol. 83:791–801.
19. Johnson S, et al. 1997. Development of a humanized monoclonal anti-
body (MEDI-493) with potent in vitro and in vivo activity against respi-
ratory syncytial virus. J. Infect. Dis. 176:1215–1224.
20. Kabat EA, Wu TT, Perry MH, Gottesman KS, Foeller C. 1991. Se-
quences of proteins of immunological interest, 5th ed. U.S. Department
of Health and Human Services, Bethesda, MD.
21. Karnasuta C, et al. 2005. Antibody-dependent cell-mediated cytotoxic
responses in participants enrolled in a phase I/II Alylvac-HIV/AIDSvax
B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 23:2522–2529.
22. Lambotte O, et al. 2009. Heterogeneous neutralizing antibody and anti-
body-dependent cell cytotoxicity responses in HIV-1 elite controllers.
AIDS 23:897–906.
23. Liao HX, et al. 2012. HIV-1 envelope antibodies induced by Alylvac-
AIDSvax B/E vaccine target a site of vaccine immune pressure within the
β- strand of gp120 V1/V2, abstr 230, p 110. Keystone Symp. HIV Vac-
cines.
24. Liao HX, et al. 2011. Initial antibodies binding to HIV-1 gp41 in acutely
infected subjects are polyreactive and highly mutated. J. Exp. Med. 208:
2237–2249.
25. Liao HX, et al. 2009. High-throughput isolation of immunoglobulin
genes from single human B cells and expression as monoclonal antibodies.
J. Virol. Methods 158:171–179.
26. Ljunggren K, et al. 1990. Antibodies mediating cellular cytotoxicity and
neutralization correlate with a better clinical stage in children born to
human immunodeficiency virus-infected mothers. J. Infect. Dis. 161:
229–236.
27. Mikell I, et al. 2011. Characteristics of the earliest cross-neutralizing
antibody response to HIV-1. PLoS Pathog. 7:e1001251. doi:10.1371/jour-
nal.ppat.1001251.
28. Montefiori DC, et al. Magnitude and breadth of the neutralizing antibody
response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect.
Dis. 206:431–441.
29. Moody MA, et al. 2012. HIV-1 gp120 vaccine induces affinity maturation
in both new and persistent antibody clonal lineages. J. Virol. 86:7496–
7507.
30. Moody MA, et al. 2011. H3N2 influenza infection elicits more cross-
reactive and less clonally expanded anti-hemagglutinin antibodies than
influenza vaccination. PLoS One 6:e25279. doi:10.1371/journal.pone.0025279.
31. Moore JP, et al. 1995. A human monoclonal antibody to a complex
epitope in the V3 region of gp120 of human immunodeficiency virus type
1 has broad reactivity within and outside clade B. J. Virol. 69:122–130.
32. Munshaw S, Kepler TB. 2010. SoDA2: a Hidden Markov Model approach
for identification of immunoglobin rearrangements. Bioinformatics 26:
867–872.
33. Nag P, et al. 2004. Women with cervicovaginal antibody-dependent
cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J. Infect.
Dis. 190:1970–1978.
34. Nitayaphan S, et al. 2004. Safety and immunogenicity of an HIV subtype
B and E prime-boost vaccine combination in HIV-negative Thai adults.
J. Infect. Dis. 190:702–706.
35. O’Doherty U, Swiggard WJ, Malim MH. 2000. Human immunodefi-
ciency virus type 1 spinoculation enhances infection through virus bind-
ing. J. Virol. 74:10074–10080.
36. Pollara J, et al. 2011. High-throughput quantitative analysis of HIV-1 and
SIV-specific ADCC-mediating antibody responses. Cytometry A 79:603–
612.
37. Pollara J, et al. 2010. Early appearance of ADCC- and ADCVI-mediating
antibody responses against autologous HIV-1 transmitted/founder virus.
AIDS Res. Hum. Retrovir. 26:A-12.
38. Pollara J, et al. 2011. Ontogeny, breadth and specificity of circulating
ADCC-mediating antibodies in HIV-1 infected individuals. AIDS Res.
Hum. Retroviruses 27:A-66.
39. Rerks-Ngarm S, et al. 2009. Vaccination with ALVAC and AIDSvAX to
prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209–2220.
40. Robinson JE, Elliott DH, Martin EA, Mcken K, Rosenberg ES. 2005.
High frequencies of antibody responses to CD4 induced epitopes in HIV
infected patients started on HAART during acute infection. Hum. Anti-
bodies 14:115–121.
41. Scheid JF, et al. 2011. Sequence and structural convergence of broad and
potent HIV antibodies that mimic CD4 binding. Science 333:1633–1637.
42. Shen X, et al. 2009. In vivo gp41 antibodies targeting the 2FS monoclonal
antibody epitope mediate human immunodeficiency virus type 1 neutral-
ization breadth. J. Virol. 83:3617–3625.
43. Shields RL, et al. 2001. High resolution mapping of the binding site on
human IgG1 for Fc gamma RI, Fc gamma RI, Fc gamma RIII, and FcRn
and design of IgG1 variants with improved binding to the Fc gamma R J.
Biol. Chem. 276:6591–6604.
44. Smith TF, Waterman MS. 1981. Identification of common molecular subsequences. J. Mol. Biol. 147:195–197.
45. Sun Y, et al. 2011. Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. J. Virol. 85:6906–6912.
46. Thali M, et al. 1993. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67:3978–3988.
47. Trkola A, Matthews J, Gordon C, Ketas T, Moore JP. 1999. A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J. Virol. 73:8966–8974.
48. Volpe JM, Cowell LG, Kepler TB. 2006. SoDA: implementation of a 3D alignment algorithm for inference of antigen receptor recombinations. Bioinformatics 22:438–444.
49. Whittle JR, et al. 2011. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc. Natl. Acad. Sci. U. S. A. 108:14216–14221.
50. Wrammert J, et al. 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453:667–671.
51. Wu X, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856–861.
52. Wu X, et al. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333:1593–1602.
53. Wyatt R, et al. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69:5723–5733.
54. Yagita M, et al. 2000. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 14:922–930.